norcantharidin has been researched along with Cancer of Kidney in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, S; Ren, Y; Tuergong, G; Wang, X; Weng, G; Zhu, H | 1 |
| Cai, X; Chen, S; Chen, X; Chen, Y; Deng, T; Huang, X; Li, H; Li, J; Mo, L; Zheng, D | 1 |
2 other study(ies) available for norcantharidin and Cancer of Kidney
| Article | Year |
|---|---|
Norcantharidin induces G2/M arrest and apoptosis via activation of ERK and JNK, but not p38 signaling in human renal cell carcinoma ACHN cells.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Humans; Kidney Neoplasms; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; p38 Mitogen-Activated Protein Kinases; Signal Transduction; Time Factors | 2021 |
Norcantharidin counteracts acquired everolimus resistance in renal cell carcinoma by dual inhibition of mammalian target of rapamycin complex 1 and complex 2 pathways in Vitro.
Topics: Basic Helix-Loop-Helix Transcription Factors; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Everolimus; Humans; Kidney Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Proto-Oncogene Proteins c-akt; Signal Transduction | 2022 |